California State Teachers Retirement System Increases Position in Elanco Animal Health Incorporated $ELAN

Key Points

• California State Teachers Retirement System increased its Elanco Animal Health position by 22.9% in the first quarter, bringing its holdings to 576,936 shares worth approximately $13.8 million. Institutional investors collectively own 97.48% of the stock.
• Analysts maintain a generally positive outlook, with Elanco receiving a consensus “Moderate Buy” rating and an average price target of $28.73. Recent targets range from $26 to $31.
• Elanco exceeded quarterly expectations, reporting $0.40 in adjusted EPS versus $0.34 expected and revenue of $1.37 billion, up 14.9% year over year. Shares opened at $26.42, near the company’s 52-week high of $27.72.

California State Teachers Retirement System increased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 22.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 576,936 shares of the company's stock after acquiring an additional 107,633 shares during the quarter. California State Teachers Retirement System owned approximately 0.12% of Elanco Animal Health worth $13,806,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. NewEdge Advisors LLC boosted its position in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock worth $25,000 after purchasing an additional 627 shares during the period. Root Financial Partners LLC raised its position in Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock valued at $40,000 after purchasing an additional 592 shares during the period. Uniplan Investment Counsel Inc. purchased a new position in Elanco Animal Health in the fourth quarter valued at about $41,000. Torren Management LLC acquired a new position in shares of Elanco Animal Health during the fourth quarter worth about $46,000. Finally, Bessemer Group Inc. lifted its stake in shares of Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company's stock worth $50,000 after purchasing an additional 525 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ELAN has been the subject of a number of recent research reports. Morgan Stanley increased their target price on Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 22nd. JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, May 7th. Weiss Ratings upgraded Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday. Citigroup increased their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a "buy" rating in a research report on Thursday, May 7th. Finally, Wall Street Zen downgraded shares of Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Sunday, May 24th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $28.73.

Insiders Place Their Bets

In related news, insider Rajeev A. Modi purchased 4,911 shares of the company's stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were bought at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by insiders.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $26.42 on Monday. Elanco Animal Health Incorporated has a fifty-two week low of $13.39 and a fifty-two week high of $27.72. The business has a 50 day moving average price of $24.55 and a two-hundred day moving average price of $24.07. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The firm has a market cap of $13.20 billion, a PE ratio of -52.85, a price-to-earnings-growth ratio of 1.72 and a beta of 1.68.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.Elanco Animal Health's quarterly revenue was up 14.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source